The chemical class known as SLC35F4 activators encompasses a diverse group of compounds that can influence the activity of the SLC35F4 protein, a transporter associated with nucleotide sugar transport and integral to the glycosylation process within cells. These activators can modulate the protein's function by engaging with various cellular pathways, often leading to a cascade of downstream effects that can enhance the performance of SLC35F4. The precise mechanisms by which these activators exert their influence can vary, but they typically involve alterations to cellular signaling pathways, modulation of enzyme activity within the glycosylation process, or changes in cellular transport dynamics that collectively contribute to the transporter's activation.
The modulation of SLC35F4 by these activators can occur through several mechanisms, such as increasing intracellular levels of secondary messengers like cAMP, which can initiate signaling pathways that result in the phosphorylation of proteins, including those that may interact with or regulate SLC35F4. Other compounds may disrupt the structure and function of organelles like the Golgi apparatus, thereby necessitating a compensatory response that can include the upregulation of nucleotide sugar transport. Some activators work by inhibiting enzymes involved in glycan processing, which can lead to an accumulation of substrates for glycosylation reactions and thereby increase the demand for nucleotide sugar transport. By influencing these various biochemical pathways, SLC35F4 activators can play a role in managing the flow of nucleotide sugars into the Golgi apparatus, where they are essential for the modification of proteins and lipids through glycosylation. This function is critical for maintaining proper cellular operations, including protein folding, stability, and signaling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $116.00 $179.00 $265.00 $369.00 $629.00 $1150.00 | ||
Elevates protein kinase A (PKA) activity which can phosphorylate proteins and may enhance the trafficking or activity of various SLC transporters, including the possibility of activating SLC35F4. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts Golgi structure and function, which could possibly activate SLC35F4 as a compensatory mechanism. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Alters Golgi apparatus acidity and can affect glycosylation enzymes, which could possibly activate SLC35F4 by necessitating increased nucleotide sugar transport. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Inhibits golgi alpha-mannosidase II, which could possibly activate SLC35F4 by leading to altered glycosylation demand. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Manosidase I inhibitor that alters glycan processing, which could possibly activate SLC35F4 by impacting the glycosylation pathway and nucleotide sugar transport. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Blocks N-linked glycosylation, which could possibly activate SLC35F4 by increasing the need for nucleotide sugar transporters to compensate for stress on the glycosylation machinery. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Inhibits glucosyltransferase, which could possibly activate SLC35F4 by altering glycosylation pathways. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Glycosidase inhibitor that could possibly activate SLC35F4 by creating imbalances in glycosylation. | ||||||
D-Glucosamine | 3416-24-8 | sc-278917A sc-278917 | 1 g 10 g | $201.00 $779.00 | ||
Serves as a substrate for the hexosamine biosynthesis pathway, which could possibly activate SLC35F4 by affecting glycosylation and related transport processes. | ||||||